N-Methyl-N-cyclohexylbenzolsulfonamid | 92197-60-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-Methyl-N-cyclohexylbenzolsulfonamid
• 英文别名: Benzolsulfonyl-N-methyl-N-cyclohexyl-amid；N-cyclohexyl-N-methylbenzenesulfonamide
• CAS: 92197-60-9
• 化学式: C₁₃H₁₉NO₂S
• mdl: MFCD01211966
• 分子量: 253.365
• InChiKey: QLQSOZHLFULCFT-UHFFFAOYSA-N

物化性质

• 熔点：
  75 °C
• 沸点：
  376.1±25.0 °C(Predicted)
• 密度：
  1.18±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.538
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] 2-MORPHOLINO-4-PYRIMIDONE COMPOUND<br/>[FR] COMPOSE 2-MORPHOLINO-4-PYRIMIDONE
  申请人：MITSUBISHI PHARMA CORP

  公开号：WO2006028290A1

  公开（公告）日：2006-03-16

  A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein X represents CH or N; 1 represents a C1-C12 alkyl; R2 represents a hydrogen atom, or the like; R' represents a C1-C6 alkyl or the like; q represents 0 or an integer of 1 to 7; Y represents a C1-C6 alkyl or the like; p represents 0 or an integer of 1 to 5; R represents a 2,3-dihydroindolyl or the like, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

  化合物的化学式（I）所代表的化合物，其光学活性异构体，或其药用可接受盐：其中X代表CH或N；1代表C1-C12烷基；R2代表氢原子，或类似物；R'代表C1-C6烷基或类似物；q代表0或1至7的整数；Y代表C1-C6烷基或类似物；p代表0或1至5的整数；R代表2,3-二氢吲哚基或类似物，用于预防和/或治疗由tau蛋白激酶1过度活化引起的疾病，如神经退行性疾病（例如阿尔茨海默病）。
• [EN] NEW ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS AND USES IN TREATMENTS OF OBESITY AND DIABETES MELLITUS - 087<br/>[FR] NOUVEAUX INHIBITEURS DE L'ACÉTYL COENZYME A CARBOXYLASE (ACC) ET UTILISATIONS DANS LE TRAITEMENT DE L'OBÉSITÉ ET DU DIABÈTE SUCRÉ - 087
  申请人：ASTRAZENECA AB

  公开号：WO2009082346A1

  公开（公告）日：2009-07-02

  The present invention relates to Acetyl Coenzyme A Carboxylase (ACC) inhibitors according to formula (I), or an enantiomer thereof, or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, E, L, Z and n are as defined herein, to processes for preparing such compounds, to pharmaceutical compositions containing them, to the use of such inhibitors and to methods for th eir therapeutic use, particularly in the treatments of obesity and diabetes mellitus.

  本发明涉及根据式（I）的乙酰辅酶A羧化酶（ACC）抑制剂，或其对映体，或其药用可接受的盐，其中R1、R2、R3、R4、R5、E、L、Z和n的定义如本文所述，以及制备此类化合物的方法，含有它们的药物组合物，使用这种抑制剂以及用于它们的治疗用途的方法，特别是用于肥胖和糖尿病的治疗。
• Cell adhesion inhibitors
  申请人：Biogen, Inc.

  公开号：US20040132809A1

  公开（公告）日：2004-07-08

  A cell adhesion inhibitor of the general formula: R 3 —L—L′—R 1 is disclosed. An inhibitor of the present invention interacts with VLA-4 molecules and inhibits VLA-4 dependent cell adhesion. Also disclosed are methods for preparing and using such a cell adhesion inhibitor, as well as pharmaceutical compositions containing the same.

  本发明公开了一种细胞黏附抑制剂，其一般式为：R3-L-L′-R1。本发明的抑制剂与VLA-4分子相互作用，并抑制VLA-4依赖的细胞黏附。本发明还公开了制备和使用此类细胞黏附抑制剂的方法，以及包含其的药物组合物。
• 2-MORPHOLINO-4-PYRIMIDONE COMPOUND
  申请人：WATANABE Kazutoshi

  公开号：US20090124618A1

  公开（公告）日：2009-05-14

  A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein X represents CH or N; represents a C 1 -C 12 alkyl; R 2 represents a hydrogen atom, or the like; R′ represents a C 1 -C 6 alkyl or the like; q represents 0 or an integer of 1 to 7; Y represents a C 1 -C 6 alkyl or the like; p represents 0 or an integer of 1 to 5; R represents a 2,3-dihydroindolyl or the like, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

  化合物的化学式为（I），其手性异构体或药物可接受的盐：其中X代表CH或N；代表C1-C12烷基；R2代表氢原子或类似物；R'代表C1-C6烷基或类似物；q代表0或1至7的整数；Y代表C1-C6烷基或类似物；p代表0或1至5的整数；R代表2,3-二氢吲哚基或类似物，用于预防和/或治疗由tau蛋白激酶1过度活化引起的疾病，例如神经退行性疾病（例如阿尔茨海默病）。
• COMPOUNDS AND THERAPEUTIC USES THEREOF
  申请人：Willardsen J. Adam

  公开号：US20150353538A1

  公开（公告）日：2015-12-10

  The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders.